Zenith Epigenetics
  • About
  • Science & Epigenetics
  • Programs
  • Newsroom
  • Contact
  • Connect
    Email
    info@zenithepigenetics.com
    Call
    1 (587) 390-7865
    Share
  • FAQ
Newsroom
  • News Releases
  • Presentations & Events
  • SEDAR Filings

News Releases

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
December 14, 2016 - Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
December 14, 2016
Zenith Capital Corp. Announces Annual and Special Meeting Webcast Details
December 7, 2016
Zenith Epigenetics Corp. Announces Name Change and Internal Corporate Reorganization
August 2, 2016
Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
June 15, 2016
Zenith Epigenetics Closes $24.6 Million USD Private Placement
May 16, 2016

About

  • Overview
  • Management
  • Board of Directors

Science & Epigenetics

  • What is Epigenetics?
  • BET Inhibitors & Oncology
    • Resistance & Combo Therapy
  • BET Inhibitor Platform
    • Covalent BET Inhibitors
    • Translational Medicine
  • Publications & Posters

Programs

  • Oncology Pipeline
    • Prostate Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Lung Cancer
    • Other Solid Tumor Cancers
  • Partnerships & Collaborations

Newsroom

  • News Releases
  • Presentations & Events
  • SEDAR Filings

Contact

  • Contact
  • Careers
  • Shareholder FAQ

© 2025 zenithepigenetics | Legal | Privacy

Bookmark and Share